In President Moshe Katsav's address to an audience of approximately 200 people, which included employees of Medis, their families and other invited guests, President Katsav pointed out how important contributions of technologically innovative companies like Medis are to the expansion of business and employment in the State of Israel. Then, President Kastav, together with the Aid-Decamp to the President, General Shimon Hefetz, Moshe Keret, President and CEO of Israel Aircraft Industries, and Mr Lifton were taken on a guided tour of the new facilities by Mr. Gennadi Finkelshtain, the Chief Technology Officer of Medis Technologies.

Mr. Lifton noted in his remarks that, "We are proud to share this milestone in the development of our Company with the President of the State of Israel. With this new modern facility we are prepared to enter the next stage of our program, to move to production and commercialization of our first products, the disposable Power Pack for advanced electronic devices, as well as our first military Power Pack applications for ruggedized hand held devices used by the US military."

Medis Technologies is involved in the development of highly advanced proprietary technology products primarily related to sources of clean energy for the 21st Century. Medis' primary focus is on direct liquid fuel cell technology. Its business strategy is to license or sell its technologies to, or enter into joint ventures with, large international corporations or sell its products to end users through retail outlets and service providers. In addition to its fuel cell technology, Medis' product pipeline, in varying stages of development, includes inherently conductive polymers, the toroidal engine and compressor and stirling cycle system. Medis has also developed the CellScan with many potential applications relating to disease diagnostics and chemo sensitivity.

This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risk and uncertainties, including, but not limited to, the successful completion of product development, the success of product tests, commercialization risks, availability of financing and results of financing efforts. Further information regarding these and other risks is described from time to time in the Company's filings with the SEC.

This press release is available on Medis' web site at www.medistechnologies.com.

SOURCE: Medis Technologies Ltd

Medis Technologies Inc.
Robert K. Lifton, 212/935-8484
or
Investor Relations Counsel:
The Equity Group
Adam Prior, 212/836-9606
Devin Sullivan, 212/836-9608